Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

PLx Pharma, Inc. (PLXPQ) had Revenue of $8.21M for the most recently reported fiscal year, ending 2021-12-31.

Quarterly Annual

Figures for fiscal year ending 2021-12-31

Income Statement Financials
Revenue	$8.21M
Net Income	$-48.65M
Cost of Goods Sold	$4.80M
Gross Profit	$3.40M
Operating Expenses	$49.00M
Operating Income	$-40.79M
Non-Operating Income/Expense	$-5.33M
Pre-Tax Income	$-46.12M
Normalized Pre-Tax Income	$-46.12M
Income after Taxes	$-46.12M
Income from Continuous Operations	$-46.12M
Consolidated Net Income/Loss	$-46.12M
Normalized Income after Taxes	$-46.12M
EBIT	$-40.79M
EBITDA	$-40.57M
Weighted-Average Shares Outstanding (Basic)	23.65M
Weighted-Average Shares Outstanding (Diluted)	23.65M
Earnings per Share (EPS) (Basic)	$-2.06
Earnings per Share (EPS) (Diluted)	$-2.06
Balance Sheet Financials
Current Assets	$73.48M
Property, Plant, and Equipment	$0.86M
Long-Term Assets	$3.17M
Total Assets	$76.64M
Current Liabilities	$11.88M
Long-Term Debt	--
Long-Term Liabilities	$29.10M
Total Liabilities	$40.98M
Common Equity	$35.67M
Tangible Shareholders Equity	$33.60M
Shareholders Equity	$35.67M
Common Shares Outstanding	27.54M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-32.12M
Cash Flow from Investing Activities	$0.10M
Cash Flow from Financial Activities	$78.97M
Beginning Cash	$22.45M
End Cash	$69.39M
Increase/Decrease in Cash	$46.94M
Stock-Based Compensation	$2.88M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.19
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	41.46%
Operating Margin	-496.95%
EBIT Margin	-496.95%
EBITDA Margin	-494.32%
Pre-Tax Profit Margin	-561.95%
Profit Margin	-592.71%
Free Cash Flow	$-32.02M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	1.95
Receiveable Turnover	12.95
Days Sales in Receivables	28.19
Return on Equity	-129.32%
Return on Tangible Equity	-137.26%
Return on Assets	-60.18%
Return on Investments	-129.32%
Book Value Per Share	$1.30
Free Cash Flow per Share	$-1.35
Operating Cash Flow per Share	$-1.36

Data from Zacks Investment Research, Inc.